Company news

Glaukos Corporation news in 2025

Glaukos Corporation's news releases, calls and decks from 2025, newest first.

View company

Glaukos Announces Participation in J.P. Morgan Healthcare Conference

December 16, 2025

Sudo Biosciences Appoints Paul Bavier as Chief Legal Counsel

December 4, 2025

Glaukos Announces Participation in Upcoming Investor Conferences

November 3, 2025

Glaukos Announces Third Quarter 2025 Financial Results

October 29, 2025

Glaukos Announces FDA Approval of Epioxa™

October 20, 2025

Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting

October 14, 2025

Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29

October 8, 2025

Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama

September 25, 2025

Glaukos Announces Participation in Wells Fargo Healthcare Conference

August 13, 2025

Glaukos Announces Second Quarter 2025 Financial Results

July 30, 2025

Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30

July 9, 2025

FELIQS Appoints Gregory Kunst and Joe Zenkus to Board of Directors

July 8, 2025

Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies

June 25, 2025

Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell

June 25, 2025

Glaukos Announces First Quarter 2025 Financial Results

April 30, 2025

Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

April 23, 2025

Glaukos Announces the Release of its 2024 Sustainability Report

April 16, 2025

Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

April 9, 2025

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

February 24, 2025

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

February 20, 2025

Calls in 2025

Decks in 2025